Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

RSS » New York Times News » NYTHealth

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

July 23, 2025

18-fda-duchenne-mediumSquareAt3X-NJMqB0-rss

 The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Elevidys, after three patients died from liver failure after taking it or a similar treatment.  

Creator: The New York Times (NYTHealth)

Source URL

Related Posts

  • One Health Insights
Wastewater Disease Surveillance Reveals Hidden Threats
Wastewater Disease Surveillance
  • Technology and Digital Health
Satellite Health Monitoring Reveals Risks From Space
Satellite Health Monitoring
  • Events and Conferences
Major One Health Conferences to Attend in September 2026
One Health Conferences September 2026

Most Recent

  • Book and Article Reviews
One Health Book Review: A Comprehensive Analysis 
One Health Book Review
  • Careers
Value of MPH in One Health: Career Benefits and Impact
Value of MPH in One Health
  • Community Stories
Malaria Control Strategies: One Health in Action
Malaria Control Community Stories

Spheres of Focus

Infectious Diseases

Climate & Disasters

Food &
Water

Natural
Resources

Built
Environments

Technology & Data

Featured Posts